Skip to main content

Table 2 Myocardial infarctions identified by the clinical events committee but not the site investigator

From: Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study

 

Eastern Europe

Latin America

North America

Western Europe

Overall

Clinical scenario

(n = 182)

(n = 44)

(n = 299)

(n = 291)

(n = 816)

Asymptomatic CK-MB elevation*

83 (46)

23 (52)

37 (12)

128 (44)

271 (33)

Ischemic event†

89 (49)

12 (27)

48 (16)

68 (23)

217 (27)

Coronary artery bypass graft-related

6 (3)

6 (14)

138 (46)

52 (18)

202 (25)

PCI-related

2 (1)

1 (2)

62 (21)

22 (8)

87 (11)

Early myocardial infarction‡

1 (1)

0 (0.0)

3 (1)

3 (1)

7 (1)

Isolated electrocardiogram (Q waves)§

1 (1)

1 (2)

5 (2)

4 (1)

11 (1)

Peri-death¶

0 (0)

1 (2)

1 (0.3)

4 (1)

6 (1)

Miscellaneous

0 (0)

0 (0)

5 (2)

10 (3)

15 (2)

  1. Data presented as n (%). CK-MB, CK-MB = creatine kinase-myocardial band; PCI, percutaneous coronary intervention. * No clinical symptoms or electrocardiography (ECG) evidence of ischemia. † Clinical evidence of ischemia and ECG/cardiac enzyme evidence of infarction. ‡ Cardiac enzyme or ECG evidence of infarction < 24 hours after enrolment, different from the enrolment event. § Identified by systematic review of ECGs without clinical evidence of reinfarction. ¶ Myocardial infarction at the time of death with clinical, ECG, or cardiac enzyme evidence.